ChemoCentryx Inc. (CCXI) announced the peer-reviewed publication of positive data from its Phase 2 CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis or RA. The findings showed that CCX354 was generally well tolerated by patients with RA.
Measurement of evidence of clinical activity included the ACR20 response at Week 12 in patients who met trial inclusion criteria at the start of dosing: The response was 56% in patients receiving 200 mg CCX354 once daily, versus 44% in patients receiving 100 mg twice daily and 30% in patients receiving placebo. ACR20 is a standard measure of improvement in tender and swollen joint counts. The difference between 200 mg once daily and placebo was statistically significant.
Also, the data indicated that CCX354 treatment reduced markers of bone turnover, supporting the previously documented role of CCR1 in osteoclast maturation and migration.
"Results from the CARAT-2 study have demonstrated clinical proof-of-concept of CCR1 inhibition in the treatment of RA," stated Thomas Schall, President and Chief Executive of ChemoCentryx.
by RTT Staff Writer
For comments and feedback: email@example.com